Acta Biomaterialia Submission Guide

Source: Acta Biomaterialia on ScienceDirect, accessed May 27, 2026.

Source: Acta Biomaterialia Guide for Authors.

Use this page when deciding:

• whether the biomaterial advance is substantive

• whether biological validation is rigorous

• whether biological interface is characterized

• a clear biomaterial advance

• rigorous biological validation

• biological-interface characterization

• biomaterial focus

• a cover letter establishing the contribution

• Incremental materials reports without biological validation.

• Weak biocompatibility data.

• Missing in-vivo evaluation.

• General materials without biological focus.

Acta Biomaterialia is a flagship biomaterials journal.

Biological-validation standard: the journal differentiates from Biomaterials (broader high-impact) and Journal of Biomedical Materials Research (broader applied) by demanding biomaterial advances with biological validation.

In-vivo expectation: editors expect biological characterization including in-vivo where appropriate.

Rapid editorial screen: the abstract, graphical abstract, and first biological-validation figures need to prove the biomaterials-and-biology balance quickly.

The strongest Acta Biomaterialia editor-fit notes establish:

• the biomaterial advance

• the biological validation

• the biological-interface mechanism

• the central finding

Acta Biomaterialia requires these at first submission:

• editable manuscript source file (.docx or .tex, not PDF) within the 10-printed-page envelope

• cover letter establishing the biomaterials advance and the biological validation that distinguishes it from materials-only journals

• mandatory graphical abstract showing the biomaterials advance pictorially

• highlights file (3-5 bullet points, 85 characters each)

• author byline with ORCID iDs and CRediT contribution statement

• declaration of competing interests

• ethics statements for animal protocols (IACUC), human-subjects work (IRB), and informed consent

• biosafety declarations for any work with regulated organisms or bloodborne pathogens

• data availability statement covering materials-characterization data, in vitro cell-culture data, in vivo data, and any imaging or biomechanical datasets

• suggested reviewers with institutional affiliations and email addresses

• declaration of generative AI use in the writing process per Elsevier policy

• optional SSRN preprint opt-in (manuscript posts publicly once it enters peer review)

• for revised submissions, point-by-point reviewer response and marked-up manuscript

For Acta Biomaterialia submissions, the most common artifact-related issue is the graphical abstract showing the materials chemistry but not the biological validation. The journal's mandatory graphical-abstract policy is paired with editorial expectations that the graphical abstract communicate the biology-materials integration in a single image; submissions where the graphical abstract is a synthesis schematic without biological readout face desk-screen returns even when the underlying biology is solid.

Acta Biomaterialia manuscripts move through a four-stage editorial timeline. The journal's stated commitment to rapid peer-review compresses the workflow.

Day 0 to 5: Editorial Manager intake and technical check

The platform performs automated checks (source-file format, mandatory graphical abstract, page count against the 10-printed-page envelope, declarations, ethics references). PDF source files and submissions exceeding the page envelope are returned at this stage.

Day 5 to 21: Editor-in-Chief or Associate Editor desk-screen

An Associate Editor (matched to the manuscript's biomaterials subfield: tissue engineering, drug delivery, biointerfaces, biomedical devices, regenerative medicine, or computational biomaterials) reviews scope fit, the biomaterials-and-biology balance, and the rigor of the biological validation. Materials-only submissions with weak biology are routinely transferred via Elsevier's Article Transfer Service to Materialia (the sibling materials-only journal) or to Acta Materialia for purely structural-materials work.

Week 4 to 8: External peer review

Manuscripts that pass desk-screen go to 2-3 reviewers selected for both materials and biology expertise. Reviewer turnaround supports the journal's rapid-review commitment.

Week 8 to 16: Decision and revision rounds

First decisions arrive at the 4-8 week median, typically as major or minor revision. Revision cycles add 4-10 weeks. Authors may file a formal appeal per Elsevier's Appeal Policy (one appeal per submission, decision final).

• Is Acta Biomaterialia a good journal?

• Acta Biomaterialia overview

• Biomaterials Submission Guide

• Biomaterials Science Submission Guide

• Acta Materialia Submission Guide

• Journal of Controlled Release Submission Guide for delivery manuscripts where release behavior is the main claim rather than biomaterial function.

Before upload, run your manuscript through an Acta Biomaterialia biological readiness check.

Across biomaterials manuscripts targeting Acta Biomaterialia, three patterns generate the most consistent desk-screen risk.

Materials chemistry without biological function

Across biomaterials manuscripts targeting Acta Biomaterialia, the first recurring risk is a strong materials-chemistry or fabrication paper whose biological function is too thin for the journal. Acta Biomaterialia is not simply a high-impact materials outlet; the Guide for Authors describes the journal as a biomaterials venue and the ScienceDirect page positions it in the broadly defined field of biomaterials science. A manuscript can report strong mechanical, surface, degradation, porosity, drug-loading, or nanostructure data and still feel misrouted if the biology is a small add-on.

The repair is to make the biological question visible in the abstract, graphical abstract, figures, and cover letter. The abstract should name the biomaterial, target tissue or biological interface, intended function, validation model, and biological readout. The graphical abstract should show both the materials design and the biological outcome, not only synthesis or device architecture.

The methods should give enough cell, tissue, animal, imaging, statistics, and ethics detail for reviewers to trust the biological claim. Figures should connect material properties to adhesion, viability, immune response, regeneration, release behavior, integration, or functional recovery.

If the contribution is mainly structural materials, polymer chemistry, surface engineering, or device fabrication without biological validation, Acta Materialia, Materialia, Biomaterials Science, Journal of Biomedical Materials Research, or a specialist materials journal may be a better target.

Check whether your Acta Biomaterialia biological-function claim is visible enough →

Graphical abstract misses the biology

Across Acta Biomaterialia-targeted manuscripts, the second recurring risk is treating the graphical abstract as a decorative synthesis schematic. The Guide for Authors requires a graphical abstract, and that artifact is often the fastest way editors see whether the manuscript integrates biomaterial design with biological response. If the graphical abstract only shows a particle, scaffold, coating, hydrogel, implant, or fabrication sequence, the biology-materials integration is not doing enough editorial work.

The repair is to make the graphical abstract a one-image claim. It should show the material design, biological interface, validation model, and final biological or functional readout. The main figures should then carry the same logic: one figure for material characterization, one for biological response, one for mechanism or interface behavior, and one for functional or translational consequence. The cover letter should state how the graphical abstract proves Acta Biomaterialia fit.

The supplementary material should not be the only place where biocompatibility, controls, sample sizes, or imaging support appear. If the image can be understood without the biological readout, the manuscript may still be a materials paper rather than an Acta Biomaterialia paper.

Check whether your Acta Biomaterialia graphical abstract carries the biology →

Validation package underpowered for the claim

For manuscripts targeting Acta Biomaterialia, the third recurring risk is a validation package that does not match the translational claim. Authors often write toward tissue engineering, drug delivery, implants, wound healing, immunomodulation, antibacterial activity, or regenerative medicine while the data only support a narrower in vitro or short-term compatibility claim. The issue is not always the absence of in vivo data; it is often that the abstract, discussion, and cover letter overstate what the validation model can prove.

The repair is proportional claim discipline. The methods should specify cell type, animal or human tissue source where applicable, controls, sample size, randomization or blinding where relevant, imaging quantification, statistics, and ethics approvals. The figures should compare against clinically or biologically meaningful controls, not only against untreated or blank-material groups. The discussion should separate material advance, biological response, mechanism, and translational readiness. The cover letter should be honest about what has and has not been validated.

If the manuscript needs a broader biomedical device, drug-delivery, tissue-engineering, or clinical translational audience, Biomaterials, Advanced Healthcare Materials, Bioactive Materials, Journal of Controlled Release, or a specialty tissue-engineering journal may be stronger.

Check whether your Acta Biomaterialia validation package matches the claim →

Check whether your Acta Biomaterialia manuscript is submission-ready →

Clarivate JCR 2024 bibliometric data places Acta Biomaterialia among top biomaterials journals.

In pre-submission diagnostic work for top biomaterials journals, we consistently see four signals that distinguish strong submissions from weak ones. First, the biomaterial advance must be substantive. Second, biological validation should be rigorous. Third, in-vivo evaluation should be included for practical claims. Fourth, biological-interface mechanism should be characterized.

For Acta Biomaterialia-targeted manuscripts, the single most consistent feedback class we deliver in pre-submission diagnostics for Acta Biomaterialia is the materials-versus-biomaterial distinction. Acta Biomaterialia editors expect biological validation. Submissions framed as "we developed material X with property Y" without biological data routinely receive "where is the biological validation?" feedback. We coach authors to integrate biological evidence as central. Papers framed as "we developed biomaterial X for application Y, validated through cellular, biocompatibility, and in-vivo analysis" receive better editorial traction.

For Acta Biomaterialia-targeted manuscripts, beyond the rubric checks, three pre-submission diagnostic patterns recur most often in the manuscripts we review for Acta Biomaterialia. First, manuscripts where the abstract reports materials properties without biological data are flagged. Second, manuscripts where in-vivo data is reported only in supplementary materials are flagged. Third, manuscripts that lack engagement with Acta Biomaterialia's recent issues are at risk of being told the contribution doesn't fit.

The Acta Biomaterialia submissions we coach toward acceptance distinguish themselves on three operational behaviors. First, the mandatory graphical abstract communicates the materials advance AND the biological outcome in one image, since Associate Editors use the graphical abstract during the rapid-review desk-screen to triage the biomaterials-and-biology balance. Second, the cover letter names a clinical or translational indication (regenerative target, drug-delivery indication, device application) within the first 80 words, not just the materials chemistry.

Third, the recent-literature engagement names at least 3 Acta Biomaterialia papers from the past 18 months on the adjacent biomaterial system to demonstrate the work advances beyond what the journal has already published.

Acta Biomaterialia's rapid-review commitment makes the abstract, the graphical abstract, and the first paragraph of the discussion do disproportionate work at the desk-screen stage. Associate Editors triage on the biomaterials-and-biology balance: pure materials submissions with deferred biology trigger Article Transfer Service routing to Materialia or Acta Materialia rather than entering substantive desk-review.

Submissions where the biological validation appears only in the supplementary, or where the in vivo work is reserved for "future studies," fare worse than submissions where the biology is in the main-text figures regardless of which discrete cell, tissue, or animal model is used.

At Acta Biomaterialia, author-team authority is read through the integration of materials chemistry and biological validation more than through bibliometric reach alone. Editors look for submissions where the author team demonstrably owns both halves of the biomaterials-biology equation (materials chemistry from the corresponding-author lab plus biological validation co-authored with a clinical or translational collaborator). Naming 3-5 recent Acta Biomaterialia papers in the introduction and explicitly framing the current submission as the next move in that biomaterials-biology conversation signals editorial fit.